SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD — Progress Note 7 — Focused Visit (Care-plan review) — Liliʻuokalani

PatientLiliʻuokalani
Date of birth1947-09-02
IdentifiersMRN HR-ET024-SYN; SSN (made up) 000-24-3086
Document date2026-08-24
AuthorKealani Morrison-Takeda, MD
CustodianSt. Posthumous Health Center

Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.

Chief Complaint

Five-month review after the stroke. [S]

History of Present Illness

Liliʻuokalani returns six weeks after her annual wellness visit, five months after the stroke. She has had no new neurological symptoms, no bleeding and no falls, and has finished arranging a new song. She takes apixaban twice daily without missed doses and does the balance exercises from the community program twice a week. Her home blood pressure averages 122/72. Her hepatitis C antibody test was negative, and her bone density scan showed osteopenia (lowest T-score -2.1 at the femoral neck) with a ten-year risk of hip fracture below the level at which medicine is advised. She would like her zoster and Tdap vaccines today. [S]

ElementDetail
EventsNo recurrence, bleeding or falls
Home blood pressureAverage 122/72 mmHg
Screening resultsHepatitis C negative; osteopenia, below the treatment threshold
FunctionComposing and playing daily
CognitionMoCA 27

Review of Systems

SystemResultFinding
NeurologicalNegativeNo weakness, numbness, speech, vision or balance problem
HematologicNegativeNo nosebleeds, bruising, black stools or blood in the urine
MusculoskeletalNegativeNo falls

3 systems reviewed. [S]

Medications

MedicationFrequencyRouteDatesStatusEvidence
Aspirin 81 mg delayed-release oral tablet, one tablet daily for 21 days, after a 325 mg loading dose in the emergency departmentOne tablet daily for 21 daysOral route2026-03-16 to 2026-04-06completedS
Clopidogrel 75 mg oral tablet, one tablet daily, after a 300 mg loading dose in the emergency departmentOne tablet dailyOral route2026-03-16 to 2026-04-20completedS
Atorvastatin 40 mg oral tablet, one tablet dailyOne tablet dailyOral route2026-03-16activeS
Losartan 25 mg oral tablet, one tablet dailyOne tablet dailyOral route2026-03-23activeS
Apixaban 5 mg oral tablet, one tablet twice dailyOne tablet twice dailyOral route2026-04-20activeS

Allergies and Intolerances

AllergyReactionStatusEvidence
No known allergyactiveS

Vital Signs

DateMeasureValueUnitProvenance
2026-08-24Body height160cmS
2026-08-24Body weight57.8kgS
2026-08-24Body mass index (BMI) [Ratio]22.6kg/m2S
2026-08-24Systolic blood pressure124mm[Hg]S
2026-08-24Diastolic blood pressure74mm[Hg]S
2026-08-24Heart rate70/minS
2026-08-24Respiratory rate16/minS
2026-08-24Body temperature36.5CelS
2026-08-24Oxygen saturation in Arterial blood by Pulse oximetry98%S

Results

DateMeasureValueUnitReference rangeFlagProvenance
2026-08-24Sodium [Moles/volume] in Serum or Plasma139mmol/L135-145 mmol/LNormalS
2026-08-24Potassium [Moles/volume] in Serum or Plasma4.3mmol/L3.5-5.1 mmol/LNormalS
2026-08-24Creatinine [Mass/volume] in Serum or Plasma0.88mg/dL0.59-1.04 mg/dLNormalS
2026-08-24Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M67mL/min/{1.73_m2}>=60 mL/min/1.73 m²NormalS
2026-08-24Glucose [Mass/volume] in Serum or Plasma94mg/dL70-99 mg/dLNormalS
2026-08-24Hemoglobin [Mass/volume] in Blood12.7g/dL11.6-15 g/dLNormalS
2026-08-24Platelets [#/volume] in Blood by Automated count22610*3/uL150-400 10*3/uLNormalS
2026-08-24Cholesterol [Mass/volume] in Serum or Plasma134mg/dL<=199 mg/dLNormalS
2026-08-24Cholesterol in LDL [Mass/volume] in Serum or Plasma by calculation62mg/dLGoal below 70 mg/dL after ischemic strokeNormalS
2026-08-24Cholesterol in HDL [Mass/volume] in Serum or Plasma57mg/dL>=50 mg/dLNormalS
2026-08-24Triglyceride [Mass/volume] in Serum or Plasma90mg/dL<=149 mg/dLNormalS
2026-08-24Total score [MoCA]27{score}S

Physical Exam

Vital signs recorded on 2026-08-24; see the Vital Signs section. [S]

SystemFinding
GeneralWell; blood pressure 124/74, pulse 70 and regular; weight 57.8 kg
CardiovascularRegular rhythm; no murmur
NeurologicalNormal speech, strength, fine finger movements and gait

Problems

ProblemClinical statusVerificationCodeProvenance
Transient weakness and clumsiness of the right hand with word-finding difficulty, lasting about 20 minutes and fully resolved, the afternoon before the visit; suspected transient ischemic attack, ABCD2 score 5 (high risk); NIH Stroke Scale 0resolvedprovisional G45.9S — Synthetic presenting problem; resolved into the stroke diagnosis when diffusion MRI showed a small infarct at the stroke clinic the next day. Not a claim about her real symptoms.
Minor ischemic stroke: a small acute infarct in the cortex of the left precentral gyrus (left middle cerebral artery territory) on diffusion MRI, embolic in pattern, with full recovery (NIH Stroke Scale 0); source found to be paroxysmal atrial fibrillation; synthetic modern episode linked to her documented death from a strokeactiveconfirmed I63.412S — Synthetic modern diagnosis made at the stroke clinic the day after the visit; the 1917 cause of death remains D.
Hypertension: told of borderline readings in past years and not treated; 156/88 mmHg at intakeactiveconfirmed I10S — Synthetic risk factor; no blood pressure from her lifetime is recorded in the cited sources.
Paroxysmal atrial fibrillation found on 30-day ambulatory monitoring after the stroke (six episodes, the longest 3 hours 10 minutes; burden about 3%); CHA2DS2-VASc 6, HAS-BLED 2activeconfirmed I48.0S — Synthetic finding on prolonged rhythm monitoring at five weeks.
Anterior nosebleed from the left side of the nasal septum four weeks after starting apixaban, stopped with pressure; hemoglobin unchanged; resolvedresolvedconfirmed R04.0S — Synthetic intercurrent problem at an unscheduled visit; a common minor bleed on an anticoagulant, not a documented illness.

Assessment and Plan

Protocol monitoring: items the monitoring protocol calls for at this visit. [S]

DomainMeasureIntervalStatusDetail
ExaminationBlood pressure in the clinic and at home (target below 130/80 mmHg) and weightEvery visitCompleted today124/74 mmHg; home average 122/72; 57.8 kg
LaboratoryPotassium and creatinine after starting an angiotensin receptor blockerAbout two weeks after starting, then every six monthsCompleted todayPotassium 4.3 mmol/L, creatinine 0.88 mg/dL (eGFR 67)
Medication safetyAntithrombotic therapy and adherenceEvery visitCompleted todayApixaban twice daily, no missed doses; no bleeding
LaboratoryAnticoagulant safety: blood count, kidney function (creatinine clearance) and liver testsBefore starting, then about every creatinine clearance / 10 months at age 75 or older (about every five months for her)Completed todayHemoglobin 12.7 g/dL, platelets 226; creatinine clearance about 48 mL/min; dose unchanged
LaboratoryLipid panel (LDL goal below 70 mg/dL)Four to twelve weeks after starting a statin, then every three to twelve monthsCompleted todayLDL 62 mg/dL, total cholesterol 134, HDL 57, triglycerides 90
SurveyCognitive screen (MoCA)After the event, again within the first year, then periodicallyCompleted todayMoCA 27 within the first year after the stroke
SurveyDepression screen (PHQ-2, PHQ-9)At the first post-stroke visit, then at least yearlyUp to datePHQ-9 4 at three months; PHQ-2 0 at the wellness visit
ExaminationNeurological status (NIH Stroke Scale at the event; modified Rankin Scale at 90 days) and new symptomsWith any changeCompleted todayNo new symptoms; examination normal
ImagingECG and prolonged rhythm monitoring for atrial fibrillationECG at baseline; at least 30 days of monitoring within six months of the eventNot indicatedAtrial fibrillation found and treated; no further monitoring needed
ExaminationFalls riskEvery visitCompleted todayNo falls; balance program twice a week
Self-managementTobacco, alcohol and physical activityEvery visitCompleted todayNever smoker; alcohol rarely; walks daily
Self-managementInfluenza vaccineYearlyDueThis season's high-dose vaccine in the autumn
Self-managementBE FAST and calling 911Every visitCompleted todayReviewed
Self-managementCulturally safe care: her choices, ʻohana involvement and Native Hawaiian healing alongside clinic careEvery visitCompleted todayHer care continues as she directs, with her ʻohana and her own practices

Goal progress:

Immunizations given today: Recombinant zoster vaccine, dose 1 of 2; Tetanus, diphtheria, and acellular pertussis vaccine (Tdap) [S]

Guideline basis: 2021 Guideline for the Prevention of Stroke in Patients With Stroke and Transient Ischemic Attack: A Guideline From the American Heart Association/American Stroke Association (2021); Primary Care of Adult Patients After Stroke: A Scientific Statement From the American Heart Association/American Stroke Association (2021); 2023 ACC/AHA/ACCP/HRS Guideline for the Diagnosis and Management of Atrial Fibrillation (2023); 2025 AHA/ACC/AANP/AAPA/ABC/ACCP/ACPM/AGS/AMA/ASPC/NMA/PCNA/SGIM Guideline for the Prevention, Detection, Evaluation and Management of High Blood Pressure in Adults (2025); CMID: Clinical Monitoring Intelligence Database, stroke and transient ischemic attack, atrial fibrillation and hypertension monographs (2026); Signs and Symptoms of Stroke (2026); Ke Ola Mamo: a Native Hawaiian Health Care System serving Oʻahu (medical care, lomilomi and community health workers) (2026); Osteoporosis to Prevent Fractures: Screening (2025); Adult Immunization Schedule by Age (2026)

Follow-up: Zoster dose 1 and Tdap given today; second zoster dose in two to six months. Influenza and COVID-19 vaccines in the autumn. Review in three months. Call 911 for any BE FAST sign. [S]